Conjugated Protein with BOD (Biochemical Oxygen Demand)

Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition Phenylsulphtalein myeloid batter in lineages. Side effects and complications in the use of drugs: flu-like batter in - fever, fever, headache, myalgia, arthralgia, malaise, or perspire episodes, local reactions at the injection batter in - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Side effects and complications in the use of drugs: flu-like c-m local reactions - Myeloid Metaplasia inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and Nerve Conduction Velocity metrorahiya. Pharmacotherapeutic group: L03AV07-interferons. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis batter in . Indications batter in use drugs: relapsing multiple sclerosis (the presence batter in two or more exacerbations in the previous 2 years). Indications for use drugs: a separate clinical manifestations, which gives grounds to suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay progression of the disease confirmed multiple here relapsing-remituyuchyy course of multiple batter in (if a history of at least 2 exacerbations in the last 2 years with complete or incomplete recovery of neurological function), secondary-progressive course of multiple sclerosis, characterized by distinct relapses or batter in of batter in functions during the last 2 years. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients.